CCRM
Daniel Chettiar, MSc., is an accomplished scientific professional specializing in biotechnology and research with extensive experience in various roles. Currently serving as Associate Scientist II at CCRM since February 2021, Daniel has held positions in process and analytical development and as a development technologist. Previously, a Quality Assurance Technician at Erie Meat Products Ltd and a Graduate Researcher at McGill University Health Centre, Daniel conducted significant research on EGFR inhibitors and neoantigen expression. Academic credentials include a Master's in Applied Biotechnology from McGill University and a Bachelor's in Biotechnology from DY Patil University. Additional experience encompasses research traineeships focusing on diagnostic kit development and phytochemical extraction.
This person is not in the org chart
CCRM
1 followers
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011. CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.